Methotrexate Is Not Superior to Placebo for Inducing Steroid-Free Remission, but Induces Steroid-Free Clinical Remission in a Larger Proportion of Patients With Ulcerative Colitis - Université Paris Cité Accéder directement au contenu
Article Dans Une Revue Gastroenterology Année : 2016

Methotrexate Is Not Superior to Placebo for Inducing Steroid-Free Remission, but Induces Steroid-Free Clinical Remission in a Larger Proportion of Patients With Ulcerative Colitis

Franck Carbonnel
Jean Frédéric Colombel
  • Fonction : Auteur
Konstantinos H. Katsanos
  • Fonction : Auteur
Maria Nachury
  • Fonction : Auteur
Gottfried Novacek
  • Fonction : Auteur
Silvio Danese
Fabrizio Bossa
  • Fonction : Auteur
Mathurin Fumery
Georgia Malamut
  • Fonction : Auteur
Martti Färkkilä
  • Fonction : Auteur
Baya Coulibaly
  • Fonction : Auteur
Olivier Dewit
  • Fonction : Auteur
Edouard Louis
  • Fonction : Auteur

Résumé

Background & Aims Parenteral methotrexate is an effective treatment for patients with Crohn’s disease, but has never been adequately evaluated in patients with ulcerative colitis (UC). We conducted a randomized controlled trial to determine its safety and efficacy in patients with steroid-dependent UC. Methods We performed a double-blind, placebo-controlled trial to evaluate the efficacy of parenteral methotrexate (25 mg/wk) in 111 patients with corticosteroid-dependent UC at 26 medical centers in Europe from 2007 through 2013. Patients were given prednisone (10 to 40 mg/d) when the study began and were randomly assigned to groups (1:1) given placebo or methotrexate (intramuscularly or subcutaneously, 25 mg weekly) for 24 weeks. The primary end point was steroid-free remission (defined as a Mayo score ≤2 with no item >1 and complete withdrawal of steroids) at week 16. Secondary endpoints included clinical remission (defined as a Mayo clinical subscore ≤2 with no item >1) and endoscopic healing without steroids at weeks 16 and/or 24, remission without steroids at week 24, and remission at both weeks 16 and 24. Results Steroid-free remission at week 16 was achieved by 19 of 60 patients given methotrexate (31.7%) and 10 of 51 patients given placebo (19.6%)—a difference of 12.1% (95% confidence interval [CI]: −4.0% to 28.1%; P = .15). The proportion of patients in steroid-free clinical remission at week 16 was 41.7% in the methotrexate group and 23.5% in the placebo group, for a difference of 18.1% (95% CI: 1.1% to 35.2%; P = .04). The proportions of patients with steroid-free endoscopic healing at week 16 were 35% in the methotrexate group and 25.5% in the placebo group—a difference of 9.5% (95% CI: −7.5% to 26.5%; P = .28). No differences were observed in other secondary end points. More patients receiving placebo discontinued the study because of adverse events (47.1%), mostly caused by UC, than patients receiving methotrexate (26.7%; P = .03). A higher proportion of patients in the methotrexate group had nausea and vomiting (21.7%) than in the placebo group (3.9%; P = .006). Conclusions In a randomized controlled trial, parenteral methotrexate was not superior to placebo for induction of steroid-free remission in patients with UC. However, methotrexate induced clinical remission without steroids in a significantly larger percentage of patients, resulting in fewer withdrawals from therapy due to active UC. ClinicalTrials.gov ID NCT00498589.

Domaines

Chimie organique

Dates et versions

hal-01303796 , version 1 (18-04-2016)

Identifiants

Citer

Franck Carbonnel, Jean Frédéric Colombel, Jérome Filippi, Konstantinos H. Katsanos, Laurent Peyrin-Biroulet, et al.. Methotrexate Is Not Superior to Placebo for Inducing Steroid-Free Remission, but Induces Steroid-Free Clinical Remission in a Larger Proportion of Patients With Ulcerative Colitis. Gastroenterology, 2016, 150 (2), pp.380-388. ⟨10.1053/j.gastro.2015.10.050⟩. ⟨hal-01303796⟩
138 Consultations
0 Téléchargements

Altmetric

Partager

Gmail Facebook X LinkedIn More